Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

Dai Maruyama,1 Kiyohiko Hatake,2 Tomohiro Kinoshita,3 Noriko Fukuhara,4 Ilseung Choi,5 Masafumi Taniwaki,6 Kiyoshi Ando,7 Yasuhiro Terui,2 Yusuke Higuchi,3 Yasushi Onishi,4 Yasunobu Abe,5 Tsutomu Kobayashi,6 Yukari Shirasugi7 and Kensei Tobinai1

Departments of 1Hematology, National Cancer Center Hospital, Tokyo; 2Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo; 3Hematology and Cell Therapy, Aichi Cancer Center, Nagoya; 4Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai; 5Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka; 6Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto; 7Hematology and Oncology, Tokai University, Isehara, Japan

Key words
Hodgkin lymphoma, immunotherapy, Japanese, nivolumab, programmed death-1

Correspondence
Dai Maruyama, Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Tel: +81-3-3542-2511; Fax: +81-3-3542-3815;
E-mail: dmaruyam@ncc.go.jp

Funding Information
Ono Pharmaceutical Co., Ltd. Clinical trial registration number: JapicCTI-142755 (Japan Pharmaceutical Information Center)

Received January 9, 2017; Revised February 27, 2017; Accepted March 1, 2017

Cancer Sci 108 (2017) 1007–1012
doi: 10.1111/cas.13230

Overexpression of programmed death-1 (PD-1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD-1-blocking antibody that inhibits the PD-1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in 17 Japanese patients with refractory/relapsed classical Hodgkin lymphoma previously treated with brentuximab vedotin. Sixteen patients were included in efficacy analyses and 17 in safety analyses. The primary endpoint was the centrally assessed objective response rate (ORR). The study was commenced in March 2015. We report data obtained at a cutoff of 16 March 2016, at which time 11 patients were still receiving nivolumab. The median (range) duration of treatment and follow-up were 7.0 (1.4–10.6) months and 9.8 (6.0–11.1) months, respectively. All 17 patients had previously received brentuximab vedotin. The ORR was 81.3% (95% confidence interval [CI]: 54.4–96.0%; 13/16 patients), with complete remission and partial remission in 4 and 9 patients, respectively. The overall survival (OS) and progression-free survival (PFS) rates at 6 months were 100 and 60.0% (95% CI: 31.8–79.7%), respectively; the median OS and PFS were not reached. The most common adverse events (AE) were pyrexia (41.2%), pruritus (35.3%), rash (35.3%) and hypothyroidism (29.4%). Four patients (23.5%) experienced grade 3 or 4 AE, but most AE were of grade 1 or 2. In conclusion, nivolumab is a potentially effective and tolerable treatment option for Japanese patients with relapsed/refractory classical Hodgkin lymphoma previously treated with brentuximab vedotin.

First-line standard treatments for classical Hodgkin lymphoma (cHL) include chemotherapy and radiotherapy, which have been reported to be curative in approximately 80% of patients.1,2 However, some patients experience disease relapse or have refractory disease. Eligible patients may undergo autologous stem cell transplantation (ASCT) after salvage chemotherapy. Patients with relapsed or refractory cHL after ASCT have a poor prognosis and the currently available conventional cytotoxic treatments are often ineffective.3

Several treatment strategies have been developed to improve the prognosis of relapsed or refractory cHL, including antibody–drug conjugates. One of these is brentuximab vedotin, which comprises a chimeric monoclonal antibody targeting CD30 linked to an antimicrotubule agent (vedotin).4,5 Several clinical trials of brentuximab vedotin have been conducted, and it is now available in several countries, including Japan, for the treatment of relapsed or refractory CD30-positive cHL. Brentuximab vedotin was associated with objective response rates (ORR) of 75% and 67% in a multinational phase II study6 and a Japanese phase I/II study,7 respectively. However, patients who experience disease progression after brentuximab vedotin usually have a poor prognosis. Indeed, median progression-free survival (PFS) and overall survival (OS) associated with the subsequent treatment following brentuximab vedotin are 3.5 and 25.2 months, respectively.8 These findings highlight the need for alternative treatment options for cHL.

The programmed death 1 (PD-1) pathway is an intracellular signaling pathway that regulates the response of activated T cells. Some cancers exploit this pathway to evade anti-tumor immune responses. Accordingly, PD-1–blocking antibodies have been developed for the treatment of solid tumors.9–11 Recent studies have also revealed the expression of PD-1 ligands in many cases of cHL as a result of amplification of 9p24.1, and that PD-1 ligand overexpression contributes to an immunosuppressive microenvironment and worse prognosis.12–16

Nivolumab, a human IgG4 anti-PD-1 monoclonal antibody, acts as an immune checkpoint inhibitor and blocks the signal
that prevents activated T cells from targeting cancer cells. A phase I study (CheckMate 039) conducted in the United States showed that nivolumab was associated with good efficacy in heavily pretreated patients with relapsed or refractory cHL, with an ORR of 87%. We report the results of a multicenter phase II study, which was designed to examine the efficacy and safety of nivolumab in Japanese patients with relapsed or refractory cHL previously treated with brentuximab vedotin.

Patients and Methods

Ethics. This study was conducted in accordance with the Helsinki Declaration, Good Clinical Practice and relevant Japanese regulations. The study was performed at seven sites in Japan, and was approved by the institutional review board at each site. All patients provided written informed consent. This study was registered with the Japan Pharmaceutical Information Center (identifier: JapicCTI-142755).

Patients. The study enrolled patients aged ≥20 years with a histopathological diagnosis of cHL. Patients with a history of treatment with ASCT, patients for whom ASCT was not indicated, and patients who refused to receive treatment with ASCT were eligible. Patients who were previously treated with brentuximab vedotin or were clinically unqualified for treatment with brentuximab vedotin even if they had not received brentuximab vedotin were eligible. Major inclusion criteria were a detectable lesion on fluorodeoxyglucose positron emission tomography (FDG-PET) and at least one lesion with a longest diameter of ≥15 mm on computed tomography (CT) or magnetic resonance imaging (MRI), Eastern Cooperative Oncology Group performance status (PS) of 0–1, life expectancy of ≥3 months, neutrophil count ≥750/mm³, platelet count ≥50 000/mm³, hemoglobin ≥8.0 g/dL, aspartate aminotransferase and alanine aminotransferase ≤3.0× the institution’s upper limit of normal (ULN), total bilirubin ≤2.0× the institution’s ULN, and creatinine ≤1.5 mg/dL or creatinine clearance ≥40 mL/min (according to the Cockcroft-Gault equation).

Major exclusion criteria were nodular lymphocyte-predominant Hodgkin lymphoma, central nervous system involvement, concurrent or history of chronic autoimmune disease, a current or past history of interstitial lung disease or pulmonary fibrosis, concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease requiring treatment, a history of organ allograft or allogeneic hematopoietic stem cell transplantation, a history of prior treatment with therapeutic antibodies or pharmacotherapies for regulation of T-cells.

Study design and treatments. Patients received their first dose of nivolumab (3 mg/kg) on Day 1 of the treatment phase, and subsequent doses were to be administered on Day 1 of each 14-day cycle. Nivolumab was to be continued if the treatment continuation criteria were met, and the trial was to continue until all patients discontinued treatment in the event of progressive disease (PD), an unacceptable adverse event (AE) or other clinically relevant reasons. However, after the first confirmation of PD or if the patient had not received a dose of nivolumab within the last 6 weeks for specific reasons or for ≥6 weeks in the case of steroid tapering after the treatment of drug-related AE, administration of nivolumab could be continued if continuation was deemed appropriate by the investigator and the patient agreed with this decision.

During treatment, CT or MRI were to be performed in cycles 4, 8, 12, 18, 24, 32, 40, 48 and 61, and every 13 cycles thereafter. FDG-PET was to be performed on Day 15 in cycles 8, 12 and 24. Patients who discontinued for reasons other than PD and whose response was complete remission (CR)/partial remission (PR)/SD at discontinuation were to undergo diagnostic imaging every 8–12 weeks, for as long as possible, until starting the next treatment for cHL or confirmation of PD or relapse.

Study measures and endpoints. The primary endpoint was the ORR assessed by a central review committee in accordance with the Revised International Working Group criteria for malignant lymphoma. The secondary endpoints included the investigator-assessed ORR, CR rate, PR rate, duration of response, time to response, PFS, OS, disappearance rate of B symptoms, median time to disappearance of B symptoms, occurrence rate of B symptoms, rate of change in the sum of the products of the greatest diameters of the target lesion, and the maximum rate of change in the sum of the products of the greatest diameters of the target lesion. We also evaluated safety endpoints, including AE, laboratory tests, vital signs, body weight, 12-lead electrocardiograph, chest X-ray and PS. AE were classified and graded according to the Common Terminology Criteria for Adverse Events version 4.0. Anti-nivolumab antibodies were determined using an electrochemiluminescence immunoassay.

Data analysis. For the purpose of this study, nivolumab was deemed to be effective if the lower bound of the 95% confidence interval (CI) calculated using the Clopper-Pearson method was above the threshold response rate of 20%. Assuming a response rate of 60%, a sample size of 15 patients was sufficient to provide a power of 90.5% with a one-sided significance level of 2.5%. Efficacy and safety data were analyzed using the efficacy and safety analysis sets, respectively. The efficacy analysis set was defined as all patients with cHL (as confirmed by the central pathological review committee or by the pathologists at the study sites) who received at least one dose of nivolumab. The safety analysis set was defined as all patients enrolled in the study who received at least one dose of nivolumab. The 95% CI for response rates was calculated using the Clopper-Pearson method. PFS and OS were estimated using the Kaplan-Meier method. All statistical analyses were performed using the SAS (version 9.3; SAS Institute, Cary, NC, USA).

Results

Patients. The study was started on 18 March 2015, and the data cutoff for these analyses was 16 March 2016. Seventeen patients were enrolled and received nivolumab. One of these patients was diagnosed with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and cHL (intermediate DLBCL/CHL) by a central pathological review committee and was excluded from the efficacy analyses, but was included in the safety analyses. The baseline characteristics of patients and their prior treatments are summarized in Table 1. The disease subtype at diagnosis (study site) was nodular sclerosis in 8 patients (47.1%), mixed cellularity in 6 (35.3%), lymphocyte depleted in 2 (11.8%), and unclassified in 1 (5.9%). The median age of the patients was 63 years (range 29–83). All of the patients had received prior chemotherapy with a median of 3 (range 2–5) regimens. All of the patients had received brentuximab vedotin, and 5 (29.4%) had previously undergone ASCT. The best overall response (BOR) to brentuximab vedotin was CR in 2 patients, PR in 5, SD in 4 and PD in 5, and was not evaluated in 1 patient.

At the time of data cutoff, 11 patients were still receiving nivolumab and 6 patients had discontinued treatment. Reasons...
Table 1. Baseline characteristics and prior treatments (safety analysis set, N = 17)

| Characteristic | Value |
|----------------|-------|
| Sex, n (%)     | Male 13 (76.5)  |
|                | Female 4 (23.5)  |
| Age, n (%)     | Median (range) 63.0 (29.8-83) |
|                | <65 years 9 (52.9) |
|                | ≥65 years 8 (47.1) |
| Time since diagnosis, months | Median (range) 24.0 (8.9-89.0) |
| ECOG PS, n (%) | 0 8 (47.1) |
|                | 1 9 (52.9) |
| Disease subtype, n (%) | Nodular sclerosis 8 (47.1) |
|                | Lymphocyte rich 0 (0.0) |
|                | Mixed cellularity 6 (35.3) |
|                | Lymphocyte depleted 2 (11.8) |
|                | Unclassified 1 (5.9) |
| Disease stage at study enrolment, n (%) | II 4 (23.5) |
|                | III 5 (29.4) |
|                | IV 8 (47.1) |
| B symptoms, n (%) | Absent 12 (70.6) |
|                | Present 5 (29.4) |
| Relapse or refractory† (to most recent therapy), n (%) | Relapse 1 (5.9) |
|                | Refractory 16 (94.1) |
| Number of prior chemotherapy regimens | Median (range) 3 (2-5) |
| Prior brentuximab vedotin | BOR to brentuximab vedotin, n (%) |
| CR 2 (11.8) | PR 5 (29.4) |
| SD 4 (23.5) | PD 5 (29.4) |
| Not evaluated 1 (5.9) |
| Prior ASCT, n (%) | CR 5 (29.4) |
| BOR to ASCT, n (%) | CR 3 (60.0) |
| SD 1 (20.0) |
| Prior radiotherapy, n (%) | 9 (52.9) |

Data are presented as the n (%), unless otherwise indicated. ASCT, autologous stem cell transplantation; BOR, best overall response; CR, complete remission; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; PR, partial remission; SD, stable disease. †Relapse indicates best response of complete remission to the most recent prior therapy, and refractory indicates best response of partial remission, stable disease, or progressive disease to the most recent prior therapy.

for treatment discontinuation were AE (2 patients, including 1 patient with interstitial lung disease), PD (2 patients) and no dose of nivolumab for more than 6 weeks after the nearest time point of dosing (2 patients). The median (range) number of doses, number of cycles, duration of treatment and relative dose intensity were 15 (4–23), 16 (4–24), 7.0 months (1.4–10.6 months) and 91.7% (79.7–101.0%), respectively.

Table 2. Tumor responses and survival rates (efficacy analysis set, N = 16)

| Tumor response | Centrally assessed | Investigator assessed |
|----------------|--------------------|-----------------------|
| CR, n (%)      | 4 (25.0)           | 3 (18.8)              |
| PR, n (%)      | 9 (56.3)           | 7 (43.8)              |
| SD, n (%)      | 1 (6.3)            | 3 (18.8)              |
| PD, n (%)      | 1 (6.3)            | 3 (18.8)              |
| Not evaluable  | 1 (6.3)            | 0 (0.0)               |
| ORR (CR + PR), % (95% CI) | 81.3 (54.4–96.0) | 62.5 (35.4–84.8) |

Progression-free survival (centrally assessed)

| Rate at 6 months, % (95% CI) | 60.0 (31.8–79.7) |
| Median (range), months        | NR (0.01–11.0) |

Overall survival

| Rate at 6 months, % | 100 |
| Median (range), weeks | 8.7 (7.1–35.9) |

Time to response (centrally assessed)

| Responders, n (%) | 13 |
| Median (range), months | 9 (69.2) |
| Ongoing responders, % | 9 (69.2) |
| Median (range), months | NR (0.01–9.2) |

CI, confidence interval; CR, complete remission; NR, not reached; ORR, objective response rate; PD, progressive disease; PR, partial remission; SD, stable disease. †Censored value. ‡Responders still showing a response at the time of data cutoff.

nivolumab was CR in 2 patients and PR in 2 patients. Because the follow-up duration was short, the median duration of response could not be calculated.

The tumor response of CR or PR was sustained in 9 out of 13 patients at the data cutoff; the remaining 4 patients experienced PD (Fig. 1). The tumor response of PR in 2 patients was sustained after discontinuation of nivolumab administration. Another patient achieved PR after discontinuation of nivolumab administration. Five patients were treated beyond progression at the data cutoff. Five patients had B symptoms at baseline (Table 1). In the 4 patients included in the efficacy analysis set, the B symptoms disappeared after administration of nivolumab in all 4 patients. The median time to disappearance of B symptoms was 8.1 weeks (range 2.3–8.1 weeks). B symptoms did not occur during treatment with nivolumab in any of the 12 patients without these symptoms at baseline.

Figure 2 shows Kaplan–Meier plots of PFS for a median follow-up of 9.8 months (range 6.0–11.1 months). Because the follow-up duration was short, the median PFS and OS were not reached at the time of the database cutoff. The PFS and OS rates at 6 months were 60.0% (95% CI 31.8–79.7%) and 100%, respectively (Table 2).

Tumor dimensions. Figure 3(a) shows a waterfall plot of tumor size, as assessed by the central review committee, in the 16 patients included in the efficacy analysis set. As indicated in this figure, the tumor shrank in 14 patients (87.5%), but not in 1 patient. The tumor size could not be assessed in 1 patient. Figure 3(b) shows the change in the sum of the diameters of the target lesion, as assessed by the central review committee. This figure shows that the tumor shrank in almost all of the patients who received nivolumab, and this shrinkage continued long term.

Anti-nivolumab antibody detection. The anti-nivolumab antibody test at baseline was positive in 1 patient; however, none of the patients had received nivolumab before the study. None
of the remaining 16 patients were positive for anti-nivolumab antibodies at any time during the administration of nivolumab.

**Safety.** Table 3 shows the AE in the safety analysis set, which comprised all 17 treated patients. All of the patients experienced 1 or more AE, the most common AE being pyrexia (7 [41.2%] of 17 patients), pruritus (6 [35.3%]), rash (6 [35.3%]) and hypothyroidism (5 [29.4%]). The majority of these were grade 1 or 2. Four patients (23.5%) experienced grade 3 or 4 AE, which included anemia, lymphopenia, thrombocytopenia, pyrexia, hepatic function abnormal, pneumonia, hyponatremia, fulminant type 1 diabetes mellitus, interstitial lung disease and rash (each 1 patient, 5.9%). There were no deaths.

Six serious AE (pyrexia, hepatic function abnormal, hyponatremia, fulminant type 1 diabetes mellitus, interstitial lung disease and rash [each 1 patient, 5.9%]) occurred in 3 patients. All of the serious AE were judged to be drug-related. Of these, interstitial lung disease and rash led to treatment discontinuation. Nivolumab was also discontinued in 1 patient owing to grade 2 peripheral neuropathy; this patient experienced peripheral neuropathy in the previous treatment with brentuximab vedotin, which was not classified as serious.

Most immune-related AE reported were of grade 1 or 2. Grade 3 or 4 immune-related AE were rash (skin disorder), fulminant type 1 diabetes mellitus (endocrine disorder) and interstitial lung disease (pulmonary disorder) in 1 patient each.

The treatment was temporarily withdrawn with a delay in subsequent doses in 7 patients (41.2%) because of AE (lymphopenia, thrombocytopenia, enterocolitis, fatigue, pyrexia,
Table 3. Adverse events with an incidence of ≥10% and immune-related adverse events (safety analysis set, N = 17)

| Category                                      | All Grade | Grade 3–4 |
|-----------------------------------------------|-----------|-----------|
|                                               | n  | %    | n  | %    |
| Hepatic function abnormal                     | 2  | 11.8 | 1  | 5.9  |
| Hyponatremia                                  | 2  | 11.8 | 1  | 5.9  |
| Malaise                                       | 2  | 11.8 |    |      |
| Myalgia                                       | 2  | 11.8 |    |      |
| Edema                                         | 2  | 11.8 |    |      |
| Upper respiratory tract inflammation          | 2  | 11.8 |    |      |
| Skin disorders                                | 8  | 47.1 | 1  | 5.9  |
| Endocrine disorders                           | 6  | 35.3 | 1  | 5.9  |
| Gastrointestinal disorders                    | 3  | 17.6 | 0  | 0    |
| Hepatic disorders                             | 2  | 11.8 | 0  | 0    |
| Pulmonary disorders                           | 1  | 5.9  | 1  | 5.9  |
| Hypersensitivity and infusion reactions        | 1  | 5.9  | 0  | 0    |
| Renal disorders                               | 0  | 0    | 0  | 0    |

AE, adverse event.

The overall safety profile of nivolumab in the present study was consistent with those reported in CheckMate 039 and CheckMate 205. Considering these findings as well as the lack of clinically meaningful changes in vital signs, physical findings and laboratory tests, nivolumab is likely to be tolerable in patients with relapsed or refractory chHL. Brentuximab vedotin is regarded as an effective drug for treating chHL, and it was associated with high ORR in several studies. For example, ORR of 75 and 67% were reported in a multinational phase II study and in a phase II study in Japan, respectively. However, the median PFS was relatively short (6,7) and might be related to inappropriate activation of T cells. Therefore, physicians should be aware of the risk of this AE in some patients, such as those with a family history of type 1 diabetes mellitus or a human leukocyte antigen haplotype associated with fulminant type 1 diabetes mellitus. Interstitial lung disease is another serious AE that occurred in our study. Pneumonitis was reported in 2 (3%) patients (1 grade 2 and 1 grade 3) in CheckMate 205. Both cases were judged to be drug-related and both resolved with corticosteroid treatment. Physicians should be vigilant for these AEs, which are characteristic of anti-PD-1 antibody therapy.
short, being 5.6 months in the multinational study and 11.1 months in the Japanese study, and a sizeable proportion of patients in both studies experienced disease relapse or had refractory disease. Considering these relatively unfavorable outcomes, there is a clear need for developing alternative treatments for cHL.

Several limitations of this study warrant mention. First, we were unable to determine the median PFS and median OS based on the available data at the data cutoff. However, this is unsurprising, because most patients were still receiving nivolumab at the data cutoff, and their response was maintained at this time. Future analyses will be conducted once additional data are available. Another possible limitation is the relatively small number of patients. However, the relatively low prevalence of cHL in Japan may make it difficult to enroll a larger number of patients. Finally, this study had an open-label, non-randomized design, but this is common in phase II studies in this setting. Randomized controlled trials and studies enrolling patients after fewer treatment regimens (e.g., before brentuximab vedotin or ASCT) may be valuable to help clarify when nivolumab should be administered in the treatment of cHL.

In conclusion, the present results indicate that nivolumab is a potentially effective treatment option for Japanese patients with relapsed or refractory cHL previously treated with brentuximab vedotin, and has an acceptable safety profile. Nivolumab was also effective in patients with a variety of cHL subtypes. Further investigation is warranted to determine the exact role of nivolumab in the treatment of cHL.

Acknowledgments

The authors thank all of the patients who participated in this study, and their families, as well as all investigators, physicians, nurses and clinical research coordinators who helped with this study. The authors are grateful to pathologists Koichi Ohshima (Kurume University Hospital, Fukuoka) and Jun-Ichi Tamura (Saitama Medical Center, Saitama) for their support in the Central Pathological Review Committee, and to Kazuo Tamura (Fukuoka University Hospital, Fukuoka), Kunihiro Tsukasaki (National Cancer Center Hospital East, Chiba), Kenichi Ishizawa (Yamagata University Faculty of Medicine, Yamagata), Terufumi Kato (Kanagawa Cancer Center, Yokohama) and Masashi Taka-rashii (Yujinkai Yujin-Yamazaki Hospital, Shiga) for reviewing the clinical data as members of the Efficacy and Safety Evaluation Committee. This study was sponsored by Ono Pharmaceutical. The authors thank Nicholas D. Smith of Edanz Group Japan K.K. for medical writing support, which was funded by Ono Pharmaceutical.

Disclosure Statement

D. Manuyama has received honoraria from Takeda Pharmaceutical and Janssen Pharmaceutical. K. Hatake has received honoraria from Ono Pharmaceutical and Kyowa Hakko Kirin, and research funding from Takeda Pharmaceutical. T. Kinoshita has received research funding from Ono Pharmaceutical. K. Ando has received research funding from Renascence, Bristol-Myers Squibb K.K. and Kyowa Hakko Kirin. Y. Shirasugi has received honoraria from Bristol-Myers Squibb K.K. and Novartis Pharma K.K. K. Tobinai has received honoraria from Takeda Pharmaceutical and research funding from Takeda Pharmaceutical, Ono Pharmaceutical and MSD K.K. All other authors have no conflicts of interest to declare.

References

1 Makita S, Maruyama D, Maeshima AM et al. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol 2016; 104: 235–40.
2 Ogura M, Itoh K, Kinoshita T et al. Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). Int J Hematol 2010; 92: 713–20.
3 Kewalramani T, Nimer SD, Zelenetz AD et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin’s disease or aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant 2003; 32: 673–9.
4 Alley SC, Okely NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 2010; 14: 529–37.
5 Atperovich A, Younes A. Targeting CD30 using brentuximab vedotin in the treatment of Hodgkin lymphoma. Cancer J 2016; 22: 23–6.
6 Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30: 2183–9.
7 Ogura M, Tobinai K, Hatake K et al. Phase II/III study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci 2014; 105: 840–5.
8 Cheah CY, Chihara D, Horowitz S et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 2016; 27: 1317–23.
9 Honet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer 2015; 112: 1421–7.
10 Jezierski Novakovic S. Checkpoint inhibitors in Hodgkin’s lymphoma. Eur J Haematol 2016; 96: 335–43.
11 Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015; 23: 32–8.
12 Chen BJ, Chapuy B, Ouyang J et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462–73.
13 Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268–77.
14 Paydas S, Bajir E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol 2015; 94: 1545–52.
15 Yamamoto R, Nishikori M, Kitawaki T et al. PD-1/PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220–4.
16 Roemer MG, Advani RH, Ligon AH et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 2016; 34: 2690–7.
17 Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015; 372: 311–9.
18 Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–86.
19 Younes A, Santoro A, Shipp M et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283–94.
20 Boll B, Gorgen H, Fuchs M et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013; 31: 1522–9.
21 Statmoullas A, Brice P, Bouabdallah R et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: Frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015; 170: 779–84.
22 Munakata W, Ohashi K, Yamauchi N, Tobinai K. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol 2017; 105: 383–6.
23 Hughes J, Vudattu N, Sznol M et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015; 38: e55–7.
24 Martin-Liber J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: A case report. Cancer Immunol Immunother 2015; 64: 765–7.
25 Miyoshi Y, Ogawa O, Oyama Y. Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med 2016; 239: 155–8.
26 Okamoto M, Okamoto M, Gotoh K et al. Fulminant type I diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 2016; 7: 915–8.